Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nonoxynol-9 gonorrhea/chlamydia prevention substantiated, joint cmte. says.

This article was originally published in The Tan Sheet

Executive Summary

NONOXYNOL-9 SAFETY, EFFICACY AS GONORRHEA/CHLAMYDIA PROPHYLACTIC SUPPORTED by existing clinical data, FDA's Non-prescription Drugs, Reproductive Health Drugs, Anti-Infective Drugs and Antiviral Drugs Advisory Committees agreed at a Nov. 20-22 joint meeting in Gaithersburg, Md. In their discussion of whether the topical vaginal spermicide is proven to provide prophylaxis from the sexually transmitted diseases gonorrhea and chlamydia, committee members voted 18-1 that N-9 is effective and 11-8 that the ingredient is safe. The group felt that five of the six studies that make up the bulk of the evidence are adequate and one is "excellent."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel